CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage…
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for…
Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration…
New patient-reported outcome data from INTEGUMENT-1 and -2 demonstrate that ZORYVE cream 0.15% rapidly decreased the impact of atopic dermatitis…
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models…
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company…
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically…
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio…
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio…
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development…